CYTH Insider Trading Activity and SEC Form 4 Filings
CYTH insider trading summary
No open-market insider purchases or sales of Cyclo Therapeutics, Inc. (CYTH) have been reported on SEC Form 4 in the past 12 months.
Latest CYTH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 1, 2023 | Rafael Holdings, Inc. | 10% Owner | Buy | $5.0M (4,000,000 @ $1.25) |
| Apr 20, 2023 | Jeffrey Tate | Chief Operating Officer | Buy | $21K (29,941 @ $0.71) |
| Apr 20, 2023 | Markus Sieger | Director | Buy | $43K (59,881 @ $0.71) |
| Apr 20, 2023 | Francis Patrick Ostronic | Director | Buy | $43K (59,881 @ $0.71) |
| Apr 20, 2023 | N Scott Fine | Chief Executive Officer | Buy | $213K (299,402 @ $0.71) |
| Sep 21, 2022 | Francis Patrick Ostronic | Director | Buy | $9K (5,000 @ $1.76) |
| May 20, 2022 | Francis Patrick Ostronic | Director | Buy | $10K (4,988 @ $2.04) |
| May 20, 2022 | Francis Patrick Ostronic | Director | Buy | $24 (12 @ $2.00) |
| May 16, 2022 | Jeffrey Tate | Chief Operating Officer | Buy | $6K (3,000 @ $2.12) |
| Apr 29, 2022 | Jeffrey Tate | Chief Operating Officer | Buy | $810 (300 @ $2.70) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.